FUJIFILM Diosynth Biotechnologies to Showcase Bio CDMO Expertise at the 2023 BIO International Convention
RESEARCH TRIANGLE PARK, North Carolina, June 1, 2023 – FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies today announced that it will showcase its bio CDMO expertise and capabilities at the 2023 BIO International Convention (BIO), booth #865, held June 5 – 8, 2023 at the Boston Convention & Exhibition Center in Boston. BIO is the largest annual event for the biotechnology and pharma industry attracting over 14,000 leaders and representatives for a week of partnering, showcasing the breadth and depth of industry innovations and networking.
This year FUJIFILM Diosynth Biotechnologies will leverage its expertise across multiple modalities to host five in-booth scientific and educational sessions led by its leaders across its global network. These sessions will cover a range of topics and the schedule is as follows:
Monday, June 5
|2:00 PM EDT||Advancing Tomorrow’s Protein Therapeutics with a Strong Formulation to Protect Them||Katherine Bowers, Ph.D.||Principal Scientist / Group Leader Analytical & Formulation Development|
Tuesday, June 6
|11:00 AM EDT||Introducing FUJIFILM Diosynth Biotechnologies’ Cell Therapy Services
|David Bolish||Site Head|
|2:00 PM EDT||Supporting Novel and Emerging Trends in Microbial Biologics||Francisco Gonzalez, Ph.D.||Associate Director, Strategic Technical Marketing|
Wednesday, June 7
|11:00 AM EDT||Advancing Tomorrow’s CMC Journey with Leading Edge Analytical Approaches||Greg Adams, Ph.D.||Sr. Director, Global Analytical Strategy and Development
|2:00 PM EDT||Novel Antibodies: Application of Efficient Strategies for the Development of more Complex Biotherapeutics||Fay Saunders, Ph.D.||Director, Mammalian Cell Culture Process Development|
In addition to the in-booth sessions, FUJIFILM Diosynth Biotechnologies will also have Commercial, Alliance Management and Recruitment team members available for partnering and career opportunity discussions.
At the convention, FUJIFILM Diosynth Biotechnologies is demonstrating its commitment to supporting local community and educational partnerships, innovation and growth in the biotechnology sector with its sponsorship of the NC Bio (booth 235) and Texas Pavilions (booth 146). NC Bio is a leading trade association that supports the life sciences community in North Carolina, while the Texas Pavilion is a prominent showcase of the state of Texas’ life sciences industry.
“As a world leading CDMO supporting our clients across the entire biopharmaceutical value chain, we look forward to BIO each year to network with leaders in our industry, and showcase our latest technologies and innovations in biologics manufacturing,” said Liza Rivera, vice president, Marketing and Communications, FUJIFILM Diosynth Biotechnologies. “With the main focus of BIO as a partnering event, we fully embrace the connections made at BIO, and anyone who stops by our booth, or engages with a team member will understand that we are living up to our company promise that we are Partners for Life – Advancing Tomorrow’s Medicines.”
Attendees are encouraged to visit FUJFILM Diosynth Biotechnologies booth #865 to attend the in-booth sessions and meet with team members.
About FUJIFILM Diosynth Biotechnologies
FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, is a world-leading contract development and manufacturing organization partner for the development and manufacture of biologics, vaccines and advanced therapies. The company operates a global network with major locations in the United States, the United Kingdom and Denmark and it is building a new manufacturing site in Holly Springs, North Carolina, USA. FUJIFILM Diosynth Biotechnologies has over thirty years of experience in the development and manufacture of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway™ microbial and Apollo™X cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. Mitsubishi Corporation is a 20% shareholder of FUJIFILM Diosynth Biotechnologies’ UK, Research Triangle Park, North Carolina, Watertown, Massachusetts and College Station, Texas sites. For more information, go to: www.fujifilmdiosynth.com.
About FUJIFILM Holdings Corporation
FUJIFILM Holdings Corporation, Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver Value from Innovation in our products and services in the business segments of healthcare, materials, business innovation, and imaging. Our relentless pursuit of innovation is focused on providing social value and enhancing the lives of people worldwide. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information about Fujifilm’s Sustainable Value Plan 2030, click here. For the year ended March 31, 2023, the company had global revenues of approximately 2.9 trillion yen (21 billion $USD at an exchange rate of 134 yen/dollar). For more information, please visit: www.fujifilmholdings.com.